Precision Pharmacotherapy and the Artificial Intelligence Revolution in the Neonatal Intensive Care Unit: Developmental Pharmacology, Drug Safety, and Generative Redesign

The Neonatal Intensive Care Unit (NICU) represents a critical frontier in modern medicine, characterized by extreme physiological fragility and a profound reliance on off-label pharmacotherapy. This review examines the current state of neonatal pharmacology through the lens of developmental pharmacology, identifying systemic barriers including cytochrome P450 ontogeny (CYP3A7 dominance in early life), renal immaturity, and altered protein binding that create unpredictable drug responses. Through a forensic analysis of the cisapride arrhythmia case, we illustrate the lethal consequences of “ontogeny-blind” drug development, where negligible CYP3A7-mediated metabolism combined with hERG potassium channel blockade (IC50: 6.5–44.5 nM) led to fatal ventricular arrhythmias. We argue that the convergence of next-generation artificial intelligence technologies—specifically AlphaFold 3 for structural biology, Large Language Models for chemical space exploration, and emerging biological World Foundation Models—provides a promising, though still maturing, pathway for addressing the “therapeutic orphan” problem. We propose a conceptual framework for “generative redesign” of therapeutics that moves from reactive post-marketing withdrawal to proactive in silico safety optimization. Critical implementation barriers including neonatal-specific training data scarcity, regulatory pathway immaturity, and the need for international consortium building are addressed with a strategic roadmap spanning near-term (2–5 years) through long-term (10+ years) development priorities.